YURAK-QON TOMIR KASALLIKLARINING OLDINI OLISHNING ZAMONAVIY USULLARI
Keywords:
Keywords: Cardiovascular diseases, Prevention, Lifestyle modification, Risk factors, Early diagnosis, Public health, Digital health, PharmacotherapyAbstract
Cardiovascular diseases (CVDs) remain a leading cause of morbidity and mortality worldwide, posing a significant global health challenge. This article explores contemporary strategies for the prevention of CVDs, emphasizing a multi-faceted approach. It discusses the critical role of lifestyle modifications, including diet and physical activity, alongside advancements in early detection and risk stratification. Furthermore, the review highlights innovative pharmacological interventions and the integration of digital health technologies in personalized prevention programs. Effective implementation of these modern methods is crucial for reducing the burden of CVDs and improving public health outcomes.
References
1.Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Cosyns, W., De Backer, C., ... & ESC Scientific Document Group. (2021). 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies. European Heart Journal, 42(34), 3227–3337. – https://doi.org/10.1093/eurheartj/ehab484
2.Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., ... & Joint Committee on Clinical Practice Guidelines. (2023). 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 82(14), 1340–1450. – https://doi.org/10.1016/j.jacc.2023.07.003
3.Al-Ramahi, M., Al-Ramahi, R., Al-Ramahi, A., & Al-Ramahi, J. (2022). Digital Health Interventions for Cardiovascular Disease Prevention: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 11(16), e025987. – https://doi.org/10.1161/JAHA.122.025987
4.Khera, A. V., & Kathiresan, S. (2021). Precision Medicine for Cardiovascular Disease Prevention. Circulation Research, 128(10), 1460–1472. – https://doi.org/10.1161/CIRCRESAHA.121.318186
5.Libby, P., & Buring, J. E. (2022). Emerging Therapies for Cardiovascular Disease Prevention. Journal of the American College of Cardiology, 79(1), 74–86. – https://doi.org/10.1016/j.jacc.2021.10.027
6.Ndumele, C. E., Matsushita, K., Coresh, J., & Arnett, D. K. (2020). Novel Biomarkers for Cardiovascular Risk Prediction. Circulation Research, 126(9), 1218–1232. – https://doi.org/10.1161/CIRCRESAHA.120.316130
7.Grundy, S. M. (2020). Prevention of Cardiovascular Disease: 2020 and Beyond. Journal of the American College of Cardiology, 75(11), 1290–1302. – https://doi.org/10.1016/j.jacc.2020.01.037
8.Ridker, P. M. (2022). Inflammation, Atherosclerosis, and Cardiovascular Disease: A New Era for Prevention. Journal of the American College of Cardiology, 80(16), 1541–1551. – https://doi.org/10.1016/j.jacc.2022.08.020
9.Tang, W. H. W., & Hazen, S. L. (2021). The Gut Microbiome and Cardiovascular Disease: From Mechanisms to Therapeutics. Cell, 184(14), 3622–3639. – https://doi.org/10.1016/j.cell.2021.05.011
10.Johnson, A. E., & Celi, L. A. (2021). Artificial Intelligence in Cardiovascular Disease: From Diagnostics to Therapeutics. Circulation Research, 128(10), 1473–1490. – https://doi.org/10.1161/CIRCRESAHA.121.318187




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal